Literature DB >> 18005851

Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells.

Dong-Gyun Lim1, In-Yi Joe, Youn-Hee Park, Sung-Ho Chang, Yu-Mee Wee, Duck-Jong Han, Song-Cheol Kim.   

Abstract

The induction of immune tolerance is one of the final therapeutic goals in clinical transplantation. Regulatory T lymphocytes are important for the induction and maintenance of immune tolerance to grafts. If immunosuppressive drugs used clinically to prevent immune rejection also inhibit regulatory T lymphocytes, tolerance would not be achieved. We therefore tested the effect of several immunosuppressants with different mechanisms of action on the proliferation and suppressive activity of CD4(+)CD25(+) regulatory T cells. Highly purified CD4(+)CD25h(+) T cells from C57BL/6 (H-2(b)) mice were stimulated with allogeneic T-depleted splenocytes (BALB/c; H-2(d)) in the presence of various immunosuppressants. After one week in culture, viable T cells were recovered, their regulatory capacity was assessed by their ability to inhibit responder T cell proliferation in MLR, and their cytokine production profile was measured by ELISA. The immunosuppressants rapamycin, cyclosporine A, and methylprednisolone significantly inhibited the expansion of regulatory T cells upon stimulation with alloantigen, whereas mycophenolic acid and the costimulatory blockers, anti-CD40L and CTLA4Ig, did not. None of these immunosuppressants, however, reduced the suppressive capacity of regulatory T cells. Pretreatment with immunosuppressants did not induce significant changes in the cytokine production profile of regulatory T cells. Our results suggest that costimulatory blockers and mycophenolate mofetil can be utilized therapeutically in the induction of immune tolerance. In contrast, the use of rapamycin, cyclosporine A, and methylprednisolone should be reconsidered, due to their deleterious effects on the expansion of naturally occurring regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005851     DOI: 10.1016/j.trim.2007.05.005

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  12 in total

1.  Rapamycin Prolongs Graft Survival and Induces CD4+IFN-γ+IL-10+ Regulatory Type 1 Cells in Old Recipient Mice.

Authors:  Markus Quante; Timm Heinbokel; Karoline Edtinger; Koichiro Minami; Hirofumi Uehara; Yeqi Nian; Haruhito Azuma; Reza Abdi; Abdallah Elkhal; Stefan G Tullius
Journal:  Transplantation       Date:  2018-01       Impact factor: 4.939

Review 2.  Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy.

Authors:  Robert Zeiser; Robert S Negrin
Journal:  Cell Cycle       Date:  2007-12-18       Impact factor: 4.534

Review 3.  Thalamus pathology in multiple sclerosis: from biology to clinical application.

Authors:  Markus Kipp; Nina Wagenknecht; Cordian Beyer; Sebastian Samer; Jens Wuerfel; Omid Nikoubashman
Journal:  Cell Mol Life Sci       Date:  2014-11-23       Impact factor: 9.261

4.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

Review 5.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

Review 6.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

Review 7.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

8.  Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro.

Authors:  P J Zhou; H Wang; G H Shi; X H Wang; Z J Shen; D Xu
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

9.  Immune response hinders therapy for lysosomal storage diseases.

Authors:  Katherine P Ponder
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

10.  T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells.

Authors:  Ashley R Sandy; Jooho Chung; Tomomi Toubai; Gloria T Shan; Ivy T Tran; Ann Friedman; Timothy S Blackwell; Pavan Reddy; Philip D King; Ivan Maillard
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.